🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Norwegian Immunotherapy in Multiple Myeloma Study

Recruitingn/aAges 18 Years - anyAllSt. Olavs Hospital
NCT06855121 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway. The aim is to close knowledge gaps, generate evidence for future clinical trials and contribute to future consensus on how to monitor for adverse events, and what mitigation strategies should be implemented, so that we can increase patient survival and quality-of-life.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion criteria * Participants age ≥ 18 years * Prior diagnosis of one of the following * Multiple myeloma as defined according to IMWG criteria * Primary plasma cell leukemia as defined according to IMWG consensus definition * AL-amyloidosis as defined according to IMWG criteria * Planned treatment with one of the following outside clinical trials (list to be amended based on approvals within the EU): * Teclistamab (Tecvayli) * Elranatamab (Elrexfio) * Talquetamab (Talvey) * Idecabtagene vicleucel (ide-cel/Abecma) * Ciltacabtagene autoleucel (cilta-cel/Carvykti) Exclusion Criteria: * None
💊

What it tests

  • Teclistamab
  • Elranatamab
  • Ciltacabtagene Autoleucel
  • Talquetamab
  • Idecabtagene vicleucel
📍

Where

23 sites
Sørlandet Hospital - Arendal
Arendal, Norway
Ålesund hospital, Department of hematology
Ålesund, Norway
Haukeland University Hospital
Bergen, Norway
Bodø Hospital
Bodø, Norway
Bærum Hospital
Bærum, Norway
Drammen hospital
Drammen, Norway
Førde hospital
Førde, Norway
Innlandet hospital trust
Gjøvik, Norway

…and 15 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy